The future of mRNA vaccine technology is uncertain after the Trump administration's opposition to vaccines, according to a Guardian editorial. The rapid development of Covid-19 vaccines, which use synthetic genetic code to train the immune system, was hailed as a major scientific success, with Katalin Karikó and Drew Weissman winning a Nobel Prize for their work.
The extensive infrastructure built during the pandemic is now being used to develop vaccines for flu, HIV and cancer. However, the second Trump administration has rejected the technology, aligning with the anti-vaccine agenda of health secretary Robert F Kennedy Jr. The US Department of Health and Human Services announced a "coordinated wind-down" of federal funding for mRNA research, cancelling an additional $500m for 22 projects.
These cuts are devastating, as developing safe therapies depends on long timelines, steady funding and predictable regulation. The abrupt reversals signal that Washington is an unreliable partner, willing to walk away after others have invested heavily. Falling vaccination rates in the US further undermine public confidence.
Despite setbacks, mRNA vaccines have shown promise. Moderna's mRNA1010 and Pfizer's modRNA outperformed standard flu jabs in final-phase trials. However, the decision on US approval, expected in early 2026, rests with the FDA's Center for Biologics Evaluation and Research, run by Vinay Prasad, a close ally of Mr Kennedy. A negative or stalled result would underscore the administration's opposition.
Meanwhile, personalised cancer vaccines are being developed, largely escaping the administration's notice as they are not viewed as "vaccines". This could provide a path forward for the technology.
